



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: HIV-1 NL4-3 ΔVpu Infectious Molecular Clone (pNL-U35)

Catalog Number: 968

Lot Number: 070012

Release Category: C

Provided: 2 µg purified plasmid DNA (0.4µg/µL)

Cloning Vector: pNL4-3 (Catalog #114), which contains 5'NY5 and 3'LAV DNA, was used as the parental plasmid.

Host Strain: HB101

Description: Contains *Sma*I (5' flanking sequences) - *Nru*I (3' flanking sequences) fragment from pNL4-3 inserted into the *Pvu*II site of pUC18. An 8 bp *Xho*I linker fragment (CCTCGAGG) was inserted into the *Ssp*I site (nt 6189) found within the *vpu* ORF of the pNL4-3 fragment. The *Xho*I linker causes a translational frame shift, resulting in premature termination 35 codons from the amino terminus of the *vpu* protein.

Special Characteristics: The size of this construct is 14,833 bp.
This clone contains a defective *vpu* gene, but is otherwise identical to the infectious molecular clone pNL4-3 and contains all other known HIV-1 genes. Transfection of this clone directs the production of infectious virus particles. Cultures should be grown in LB medium containing 100 µg/ml ampicillin.
[Plasmid map and sequence file lot 070012](#)

Recommended Storage: -20°C

Contributor: Dr. Klaus Strebel.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References: Strebel K, Klimkait T, Martin M. A novel gene of HIV-1, *vpu*, and its 16 kD product. *Science* **241**:1221-1223, 1988.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH; HIV-1 NL4-3 ΔVpu Infectious Molecular Clone (pNL-U35) from Dr. Klaus Strebel." Also include the reference cited above in any publications.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact the NIH Office of Technology Transfer, Email: NIAIDAIDSReagent@niaid.nih.gov, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated: January 26, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.